This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Novartis (NVS), Amgen (AMGN) and Bristol-Myers Squibb (BMY)

Tipranks - Sat Jun 6, 4:12AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Novartis (NVS), Amgen (AMGN) and Bristol-Myers Squibb (BMY).

Claim 55% Off TipRanks

Novartis (NVS)

TD Cowen analyst Steve Scala maintained a Hold rating on Novartis on May 18 and set a price target of $148.08. The company’s shares closed last Thursday at $148.40.

According to TipRanks.com, Scala is a 4-star analyst with an average return of 10.3% and a 62.8% success rate. Scala covers the Healthcare sector, focusing on stocks such as Merck & Company, GlaxoSmithKline, and Eli Lilly & Co. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Novartis with a $163.29 average price target, implying an 11.5% upside from current levels. In a report issued on May 28, TipRanks – Anthropic also reiterated a Hold rating on the stock with a $161.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Amgen (AMGN)

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen on May 18 and set a price target of $326.31. The company’s shares closed last Thursday at $345.60, close to its 52-week high of $346.85.

According to TipRanks.com, Werber is a 5-star analyst with an average return of 23.1% and a 58.0% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Dianthus Therapeutics, and Ionis Pharmaceuticals. ;'>

Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $361.33, representing a 4.5% upside. In a report issued on May 5, TipRanks – xAI also upgraded the stock to Buy with a $378.00 price target.

Read More on NVS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.